AKBLF (Alk-Abello AS) Change In Working Capital : $-31.9 Mil (TTM As of Mar. 2025)

View and export this data going back to 2009. Start your Free Trial

What is Alk-Abello AS Change In Working Capital?

Alk-Abello AS's change in working capital for the quarter that ended in Mar. 2025 was $-20.7 Mil.

Alk-Abello AS's change in working capital for the fiscal year that ended in Dec. 2024 was $-21.2 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Alk-Abello AS Change In Working Capital Historical Data

The historical data trend for Alk-Abello AS's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alk-Abello AS Change In Working Capital Chart

Alk-Abello AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Working Capital

Get a 7-Day Free Trial

-25.18

-4.26

-33.46

-29.70

-21.20

Alk-Abello AS Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Working Capital	Get a 7-Day Free Trial															-11.95	-13.70	-19.80	22.33	-20.73

Alk-Abello AS Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-31.9 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Alk-Abello AS Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Alk-Abello AS's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Alk-Abello AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alk-Abello AS (OTCPK:AKBLF) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

ALKBc:UK 0OIR:UK ALK B:Denmark 4AJ0:Germany

Address

Boge Alle 6-8, Horsholm, DNK, DK-2970

Website

https://www.alk.net

Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.